FIELD: medicine; pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry and medicine. Disclosed is a method of producing an antioxidant agent in the form of prolonged release, characterized in that a sifted mixture of ethyl methylhydroxypyridine succinate and hydroxypropyl methyl cellulose with viscosity of 2,700–5,040 MPa⋅with is mixed with a previously obtained moistening agent, which is an aqueous solution of hydroxypropyl methyl cellulose with viscosity of 4.8–7.2 mPa⋅s, the mixture is granulated in boiling (fluidized) layer; obtained granules are powdered with magnesium stearate and silicon with colloidal dioxide, subjected to dry granulation with subsequent pressing into tablets and film coating.
EFFECT: tablets have an improved pharmacological release profile.
4 cl, 1 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PRODUCTION OF ANTIOXIDANT PREPARATION IN FORM OF TABLET | 2020 |
|
RU2749718C1 |
PHARMACEUTICAL COMPOSITION CONTAINING ETHYLMETHYLHYDROXYPYRIDINE SUCCINATE | 2021 |
|
RU2798106C1 |
PHARMACEUTICAL COMPOSITION IN THE FORM OF A COATED TABLET | 2022 |
|
RU2786073C1 |
METHOD OF OBTAINING MEDICAL FORM OF TRIMETAZIDINE OF PROLONGED ACTION | 2012 |
|
RU2530558C2 |
PHARMACEUTICAL COMPOSITION WITH 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE FOR ORAL ADMINISTRATION AND METHOD FOR PREPARING IT | 2010 |
|
RU2444359C1 |
METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION HAVING NEUROPROTECTIVE ACTIVITY IN CHRONIC CEREBRAL ISCHEMIA | 2023 |
|
RU2816359C1 |
COMPOSITION FOR TREATING DISTURBED INNERVATION (VERSIONS) | 2013 |
|
RU2536269C1 |
PHARMACEUTICAL COMPOSITION, INCLUDING MEMANTINE AND CITICOLINE, AND ALSO A DOSAGE FORM BASED ON SPECIFIED PHARMACEUTICAL COMPOSITION, INCLUDING MEMANTINE AND CITICOLINE, METHOD OF ITS OBTAINING AND USE OF DOSAGE FORM BASED ON PHARMACEUTICAL CEUTIC COMPOSITION, INCLUDING MEMANTINE AND CITICOLINE | 2020 |
|
RU2810575C1 |
DRUG BASED ON TETRAMETILTETRAAZOBITSIKLOOKTANDION AND METHOD FOR ITS PRODUCTION | 2012 |
|
RU2611194C2 |
SYSTEM FOR DELIVERY OF 2-ETHYL-6-METHYL-3-HYDROXYPYRIDINE SUCCINATE FOR ORAL ADMINISTRATION IN FORM OF GASTRORETENTIVE TABLET | 2019 |
|
RU2734970C1 |
Authors
Dates
2020-01-29—Published
2019-06-04—Filed